Equities researchers at Barclays PLC began coverage on shares of DexCom, Inc. (NASDAQ:DXCM) in a research report issued to clients and investors on Friday, Marketbeat Ratings reports. The brokerage set an “equal weight” rating and a $76.00 price target on the medical device company’s stock. Barclays PLC’s price target would suggest a potential upside of 8.12% from the stock’s current price.

Other equities research analysts also recently issued research reports about the company. Canaccord Genuity reaffirmed a “buy” rating and set a $90.00 price objective on shares of DexCom in a research report on Wednesday, June 7th. BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, June 21st. Cowen and Company reaffirmed a “buy” rating and set a $90.00 price objective on shares of DexCom in a research report on Friday, July 14th. BMO Capital Markets reaffirmed a “buy” rating and set a $105.00 price objective on shares of DexCom in a research report on Thursday, July 13th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $78.00 price objective on shares of DexCom in a research report on Wednesday, July 12th. Seven research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $86.87.

Shares of DexCom (DXCM) traded down 2.85% during trading on Friday, reaching $70.29. 824,870 shares of the company were exchanged. The firm’s 50 day moving average is $72.47 and its 200 day moving average is $74.11. DexCom has a 1-year low of $57.68 and a 1-year high of $94.79. The firm’s market capitalization is $6.08 billion.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The company had revenue of $170.60 million for the quarter, compared to the consensus estimate of $166.54 million. During the same quarter last year, the company earned ($0.24) earnings per share. The firm’s revenue for the quarter was up 24.3% compared to the same quarter last year. On average, equities analysts anticipate that DexCom will post ($0.77) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “DexCom, Inc. (DXCM) Earns Equal Weight Rating from Analysts at Barclays PLC” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/09/15/dexcom-inc-dxcm-earns-equal-weight-rating-from-analysts-at-barclays-plc.html.

In other news, EVP Andrew K. Balo sold 3,200 shares of the firm’s stock in a transaction dated Monday, July 10th. The stock was sold at an average price of $71.55, for a total value of $228,960.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, July 12th. The stock was sold at an average price of $71.86, for a total value of $431,160.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,223 shares of company stock valued at $1,881,249. Company insiders own 1.70% of the company’s stock.

Large investors have recently made changes to their positions in the company. Morgan Stanley raised its stake in shares of DexCom by 18.0% in the first quarter. Morgan Stanley now owns 2,092,962 shares of the medical device company’s stock worth $177,336,000 after purchasing an additional 319,631 shares during the last quarter. DUPONT CAPITAL MANAGEMENT Corp purchased a new position in shares of DexCom in the first quarter worth about $270,000. Credit Suisse AG raised its stake in shares of DexCom by 0.3% in the first quarter. Credit Suisse AG now owns 302,130 shares of the medical device company’s stock worth $25,599,000 after purchasing an additional 791 shares during the last quarter. Prudential Financial Inc. raised its stake in shares of DexCom by 15.6% in the first quarter. Prudential Financial Inc. now owns 117,338 shares of the medical device company’s stock worth $9,942,000 after purchasing an additional 15,800 shares during the last quarter. Finally, HighTower Advisors LLC raised its stake in shares of DexCom by 6.1% in the first quarter. HighTower Advisors LLC now owns 33,865 shares of the medical device company’s stock worth $2,853,000 after purchasing an additional 1,949 shares during the last quarter.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.